The Experts below are selected from a list of 126 Experts worldwide ranked by ideXlab platform
John C Y Leong - One of the best experts on this subject based on the ideXlab platform.
-
strontium calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
-
Strontium–calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
Zhaoyang Li - One of the best experts on this subject based on the ideXlab platform.
-
strontium calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
-
Strontium–calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
Fergal J. O'brien - One of the best experts on this subject based on the ideXlab platform.
-
Development of collagen-hydroxyapatite scaffolds incorporating PLGA and alginate microparticles for the controlled delivery of rhBMP-2 for bone tissue engineering
Journal of Controlled Release, 2015Co-Authors: E. Quinlan, Adolfo López-noriega, Emmet Thompson, Sally-ann Cryan, Helena M. Kelly, Fergal J. O'brienAbstract:The spatiotemporally controlled delivery of the pro-Osteogenic Factor rhBMP-2 would overcome most of the severe secondary effects linked to the products delivering this protein for bone regeneration. With this in mind, the aim of the present work was to develop a controlled rhBMP-2 release system using collagen-hydroxyapatite (CHA) scaffolds, which had been previously optimized for bone regeneration, as delivery platforms to produce a device with enhanced capacity for bone repair. Spray-drying and emulsion techniques were used to encapsulate bioactive rhBMP-2 in alginate and PLGA microparticles, with a high encapsulation efficiency. After incorporation of these microparticles into the scaffolds, rhBMP-2 was delivered in a sustained fashion for up to 28 days. When tested in vitro with osteoblasts, these eluting materials showed an enhanced pro-Osteogenic effect. From these results, an optimal rhBMP-2 eluting scaffold composition was selected and implanted in critical-sized calvarial defects in a rat model, where it demonstrated an excellent healing capacity in vivo. These platforms have an immense potential in the field of tissue regeneration; by tuning the specific therapeutic molecule to the tissue of interest and by utilizing different collagen-based scaffolds, similar systems can be developed for enhancing the healing of a diverse range of tissues and organs.
Kenneth M C Cheung - One of the best experts on this subject based on the ideXlab platform.
-
strontium calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
-
Strontium–calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
W W Lu - One of the best experts on this subject based on the ideXlab platform.
-
strontium calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
-
Strontium–calcium coadministration stimulates bone matrix Osteogenic Factor expression and new bone formation in a large animal model
Journal of Orthopaedic Research, 2009Co-Authors: Zhaoyang Li, W W Lu, Peter K Y Chiu, Bing Xu, Kenneth M C Cheung, John C Y LeongAbstract:Strontium (Sr) has become increasingly attractive for use in the prevention and treatment of osteoporosis by concomitantly inhibiting bone resorption and enhancing bone formation. Strontium shares similar chemical, physical, and biological characteristics with calcium (Ca), which has been widely used as a dietary supplement in osteoporosis. However, the effects of Sr–Ca coadministration on bone growth and remodeling are yet to be extensively reported. In this study, 18 ovariectomized goats were divided into four groups: three groups of five goats each treated with 100 mg/kg/day Ca, Ca plus 24 mg/kg/day Sr (Ca + 24Sr), or Ca plus 40 mg/kg/day Sr (Ca + 40Sr), and three untreated goats fed low calcium feed. Serum Sr levels increased 6- and 10-fold in the Ca + 24Sr and Ca + 40Sr groups, respectively. Similarly, Sr in the bone increased four- and sixfold in these two groups. Sr–Ca coadministration considerably increased bone mineral apposition rate (MAR). The expression of insulin-like growth Factor (IGF)-1 and runt-related transcription Factor 2 (Runx2) was significantly upregulated within the Ca + 40Sr treatment group; tumor necrosis Factor (TNF)-agr; expression was significantly downregulated in the Ca and Ca + 40Sr groups. The results indicate that Sr–Ca coadministration increases Osteogenic gene expression and stimulates new bone formation. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27: 758–762, 2009
